Artiva Biotherapeutics is hoping to rake in up to $135 million from a planned IPO, with the proceeds ear-marked for automimmune clinical trials for a lead allogeneic natural killer (NK) cell therapy.

Destiny Pharma’s search for a partner to take its nasal infection prevention med into phase 3 has come up short, leading the British biotech to go private to avoid liquidation.

Immutep has spotted a potential niche for its LAG3 drug candidate, reporting phase 2b data in a subset of head and neck cancer patients to partly wipe away the stain left by an earlier readout.

Looking to be more upstart than startup, Element Biosciences has raised more than $277 million in new venture capital funding to help it take on the DNA sequencing giant located right down the road from its home in San Diego.

The FDA is lending its federal megaphone to an urgent medical device recall from Medtronic. The agency alerted healthcare providers to stop using certain models of the company’s endotracheal tubes, following reports that their airflow could become blocked.

The obesity game is only in its early innings, and the future market will be defined by who can ease administration of the medicines, according to a new report from Evaluate.

An R&D center in San Diego is the latest area to be impacted by Novartis’ ongoing global development restructure, the company has confirmed.

Ipsen is back with its second antibody-drug conjugate (ADC) deal of the year, this time signing a $1 billion biobucks pact with Foreseen Biotechnology for a preclinical solid tumor candidate.

Amylyx’s co-CEOs Josh Cohen and Justin Klee have already had to make what may end up being the toughest decision of their careers: withdrawing Relyvrio from the market after a late-stage study showed it was not effective in amyotrophic lateral sclerosis (ALS).

Contract research organization Allucent has been chosen as a partner for the U.S. Biomedical Advanced Research and Development Authority’s new five-year program that aims to scale up the capacity for decentralized clinical trials in preparation for future pandemics.